World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
40259
World Ranking
5613
National Ranking
3019

Glenn Heller publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Glenn Heller sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 353 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Glenn Heller D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Glenn Heller sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Glenn Heller is affiliated with Memorial Sloan Kettering Cancer Center in the United States and has contributed extensively to medical research, primarily within the field of Medicine. Their research focuses mainly on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, and Statistics and Probability.

Their work addresses a range of clinical topics, with a significant emphasis on cancer treatment and diagnosis. Major themes include:

  • Prostate Cancer Treatment and Research
  • Lung Cancer Treatments and Mutations
  • Prostate Cancer Diagnosis and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Lung Cancer Research Studies
  • PARP inhibition in cancer therapy
  • Colorectal Cancer Treatments and Studies

Heller frequently publishes in prominent oncology and clinical journals. The principal venues for their research include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • JCO Precision Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology

Recent key publications by Heller span topics in lung and prostate cancer, reflecting clinical and molecular oncology insights. Selected papers include:

  • The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer, 2020, Clinical Cancer Research
  • Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations, 2020, JCO Precision Oncology
  • Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers, 2020, JAMA Oncology
  • Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer, 2021, Clinical Cancer Research
  • The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer, 2022, Immunity

Collaboration is an important aspect of Heller's research ecosystem, with frequent co-authors including:

  • Michael J. Morris
  • Gregory J. Riely
  • Charles M. Rudin
  • Helena A. Yu
  • Mark G. Kris

These partnerships support work across various aspects of oncology, from molecular cancer characterization to therapeutic outcomes. Heller's publications and collaboration patterns highlight a commitment to advancing understanding of cancer biology and treatment modalities through multidisciplinary approaches.

Best Publications

  • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila

  • Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

    L. J. Steinherz;P. G. Steinherz;C. T C. Tan;G. Heller

  • Genomic correlates of clinical outcome in advanced prostate cancer.

    Wassim Abida;Joanna Cyrta;Joanna Cyrta;Glenn Heller;Davide Prandi

  • Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

    P A Meyers;G Heller;J Healey;A Huvos

  • Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

    Daniel C. Danila;Glenn Heller;Gretchen A. Gignac;Rita Gonzalez-Espinoza

  • Concordance probability and discriminatory power in proportional hazards regression

    Mithat Gönen;Glenn Heller

  • Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

    Howard I Scher;Howard I Scher;Xiaoyu Jia;Johann S de Bono;Martin Fleisher

  • Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

    Chad May;Stefano Rivella;John Callegari;Glenn Heller

  • Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

    Ethan Basch;Xiaoyu Jia;Glenn Heller;Allison Barz

  • Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

    Howard I. Scher;David Lu;Nicole A. Schreiber;Jessica Louw

  • Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes

    Katharine C. Hsu;Carolyn A. Keever-Taylor;Carolyn A. Keever-Taylor;Carolyn A. Keever-Taylor;Andrew Wilton;Andrew Wilton;Andrew Wilton;Clara Pinto;Clara Pinto;Clara Pinto

  • Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions

    T.N. Small;E.B. Papadopoulos;F. Boulad;P. Black

  • Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

    E Berman;G Heller;J Santorsa;S McKenzie

  • 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts

    David B. Solit;Fuzhong F. Zheng;Maria Drobnjak;Pamela N. Münster

  • Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

    Adam M. Boruchov;Glenn Heller;Maria-Concetta Veri;Ezio Bonvini

  • Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study.

    C Balmaceda;G Heller;M Rosenblum;B Diez

  • Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

    Ekaterina Doubrovina;Banu Oflaz-Sozmen;Susan E. Prockop;Nancy A. Kernan

  • Osteogenic sarcoma with clinically detectable metastasis at initial presentation.

    P. A. Meyers;G. Heller;J. H. Healey;A. Huvos

  • Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid

    Linda Vahdat;Peter Maslak;Wilson H. Miller;Anna Eardley

  • Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer

    David R Shaffer;Margaret A Leversha;Daniel C Danila;Oscar Lin

Frequent Co-Authors

Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Richard J. O'Reilly
Richard J. O'Reilly Memorial Sloan Kettering Cancer Center
Marcel R.M. van den Brink
Marcel R.M. van den Brink Memorial Sloan Kettering Cancer Center
Nancy A. Kernan
Nancy A. Kernan Memorial Sloan Kettering Cancer Center
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center
Nai-Kong V. Cheung
Nai-Kong V. Cheung Memorial Sloan Kettering Cancer Center
Katharine C. Hsu
Katharine C. Hsu Memorial Sloan Kettering Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Michel Sadelain
Michel Sadelain Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re enthusiastic about a career in healthcare but not certain medical school is the only path, there are a variety of related online degrees and certifications that can prepare you for in-demand roles. For those who want to advance their nursing careers, enrolling in a 1 year dnp program online offers a fast track to becoming a Doctor of Nursing Practice, often required for leadership positions.

Interested in pharmaceuticals? You can obtain your doctoral credentials and minimize student debt by searching for the cheapest online pharmacy school. This pathway can lead to a dynamic career as a licensed pharmacist.

The technological backbone of healthcare is rapidly growing. Earning a degree in health informatics will position you at the intersection of data, technology, and patient care, opening doors to roles in health data analysis and information systems management.

If you prefer a specialized skill set with flexible job options, consider pursuing a medical coding certification. This qualification can be attained quickly online and is highly valued in hospitals, clinics, and private practices. Each of these online options offers a viable alternative to traditional medical studies and helps you build a rewarding healthcare career.

Best Scientists Citing Glenn Heller

Trending Scientists

Recently Published Articles